Abstract
© 2019 Elsevier España, S.L.U. Immunotherapy is changing the treatment of acute lymphoblastic leukaemia (ALL) in adults and children. However, regardless of these new therapies, allogeneic hematopoietic cell transplantation (allo-HCT) still play a key role in the treatment of ALL, although it is uncertain how these new therapies will impact on the transplant procedure and indications. This article reviews the indications of allo-HCT for children and adults diagnosed with ALL, the different sources and conditioning regimens for transplantation as well as the role of measurable residual diseases pre- and post-HCT in the era of the new therapies for ALL.
Original language | English |
---|---|
Pages (from-to) | 28-34 |
Journal | Medicina Clinica |
Volume | 153 |
Issue number | 1 |
DOIs | |
Publication status | Published - 5 Jul 2019 |
Keywords
- Acute lymphoblastic leukaemia
- Allogeneic transplantation
- CAR-T
- Immunotherapy
- Monoclonal antibodies